Chemical formula: C₁₄H₁₃ClF₆N₆ Molecular mass: 414.079 g/mol PubChem compound: 117817422
Vorasidenib is indicated for:
Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Voranigo as monotherapy is indicated for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged 12 years and older and weighing at least 40 kg who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Vorasidenib is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.